Alphamab Oncology Past Earnings Performance
Past criteria checks 0/6
Alphamab Oncology has been growing earnings at an average annual rate of 11.3%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 65.4% per year.
Key information
11.3%
Earnings growth rate
23.9%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 65.4% |
| Return on equity | -12.6% |
| Net Margin | -96.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding
Jun 20
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up
May 06Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt
Oct 05Is Alphamab Oncology (HKG:9966) Using Too Much Debt?
May 05How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?
Feb 09
Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?
Dec 30What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?
Nov 25Revenue & Expenses Breakdown
How Alphamab Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 219 | -211 | 80 | 407 |
| 30 Sep 23 | 234 | -214 | 78 | 427 |
| 30 Jun 23 | 250 | -218 | 76 | 446 |
| 31 Mar 23 | 208 | -272 | 82 | 457 |
| 31 Dec 22 | 167 | -326 | 87 | 468 |
| 30 Sep 22 | 183 | -309 | 85 | 467 |
| 30 Jun 22 | 200 | -292 | 83 | 466 |
| 31 Mar 22 | 173 | -352 | 80 | 473 |
| 31 Dec 21 | 146 | -412 | 78 | 481 |
| 30 Sep 21 | 73 | -502 | 77 | 455 |
| 30 Jun 21 | 0 | -592 | 76 | 429 |
| 31 Mar 21 | 0 | -510 | 77 | 380 |
| 31 Dec 20 | 0 | -428 | 78 | 331 |
| 30 Sep 20 | 1 | -652 | 106 | 288 |
| 30 Jun 20 | 2 | -877 | 134 | 245 |
| 31 Mar 20 | -1 | -851 | 132 | 208 |
| 31 Dec 19 | 5 | -833 | 118 | 167 |
| 30 Sep 19 | 3 | -495 | 80 | 131 |
| 30 Jun 19 | 1 | -157 | 41 | 95 |
| 31 Mar 19 | 6 | -176 | 29 | 80 |
| 31 Dec 18 | -1 | -150 | 26 | 66 |
| 31 Dec 17 | 1 | -33 | 13 | 53 |
Quality Earnings: 9966 is currently unprofitable.
Growing Profit Margin: 9966 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9966 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.3% per year.
Accelerating Growth: Unable to compare 9966's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 9966 has a negative Return on Equity (-12.59%), as it is currently unprofitable.